Clinical Trials Logo

Testicular Neoplasms clinical trials

View clinical trials related to Testicular Neoplasms.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06318182 Active, not recruiting - Testicular Cancer Clinical Trials

Testicular Self-Examination Awareness in Young Men

Start date: December 9, 2022
Phase: N/A
Study type: Interventional

This study aims to determine the effect of education based on the health belief model on testicular self-examination awareness and health beliefs in young men. H0 Hypothesis: Education based on the health belief model has no effect on the awareness of testicular self-examination and health beliefs about testicular self-examination of young men in the experimental and control groups. H1a Hypothesis: The training based on the health belief model will increase the awareness of young men in the experimental group about testicular self-examination compared to those in the control group. H1b Hypothesis: The training based on the health belief model will increase the mean scores of the sensitivity subscale of young men in the experimental group compared to those in the control group. H1c Hypothesis: The training based on the health belief model will increase the mean scores of the benefit subscale of young men in the experimental group compared to those in the control group. H1d Hypothesis: The training based on the health belief model will increase the mean scores of the seriousness subscale of young men in the experimental group compared to those in the control group. H1e Hypothesis: The training based on the health belief model will decrease the mean scores of the barriers subscale of young men in the experimental group compared to those in the control group. H1f Hypothesis: The training based on the health belief model will increase the mean scores of the health motivation subscale of young men in the experimental group compared to those in the control group. H1g Hypothesis: The training based on the health belief model will increase the mean scores of the self-efficacy subscale of young men in the experimental group compared to those in the control group.

NCT ID: NCT05063760 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Exercise in Testicular Germ Cell Cancer Survivors

ExCell
Start date: January 15, 2020
Phase: N/A
Study type: Interventional

Regular exercise is effective in prevention & treatment of chronic diseases. Exercise can reduce late toxicity of chemotherapy, commonly found in cancer survivors, which is yet to be translated into clinical practice. Mechanisms of exercise benefits in oncologic patients are far from being elucidated, and include increase in muscle mass, reduction of fat mass, systemic inflammation and cardiometabolic risk. Synchronization of exercise adaptive response is, to an extent, mediated by bioactive molecules released from muscle, with anti-inflammatory & tumor-suppressing properties. Muscle satellite cells are a source of regeneration, muscle structural integrity & functional capacity. Phenotypes of muscle cells, such as secretory profile, lipid & glucose metabolism, mirror clinical phenotypes of the donor. Importantly, muscle cells' metabolism in vitro can be modulated by 8-12 week training in vivo. Epigenetic mechanisms regulating muscle & systemic metabolism in cancer survivors are not yet understood.

NCT ID: NCT04848545 Active, not recruiting - Testicular Cancer Clinical Trials

Endocrine Disrupting Chemical Exposure and Testicular Cancer

DISRUPT
Start date: June 1, 2020
Phase:
Study type: Observational

DISRUPT is a Danish nested case-control study that is currently being conducted to explore the impact of prenatal exposure to endocrine disrupting chemicals on testicular cancer risk (including histological sub-groups) with emphasis on the analysis of exposure mixtures. Pregnant mothers provided serum and amniotic fluid at recruitment up to 50 years ago. By registry linkage within highly reliable national population and disease registries cancer cases and matched controls will be identified. Levels of EDCs including DDT, DDE and other organochlorine pesticides, PCBs, PBDEs, PFAS, phthalates and triclosan will be quantified in cases whose sons develop testicular cancer during 40 year follow up and compared to controls.

NCT ID: NCT03937843 Active, not recruiting - Testicular Cancer Clinical Trials

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Start date: July 29, 2019
Phase: Phase 2
Study type: Interventional

The trial investigates a stage-adapted (stage IIA or IIB) de-escalation of the standard treatments in the context of a multimodality treatment with chemo- and radiotherapy in seminoma patients. The goal is to safely de-escalate treatment while maintaining/enhancing efficacy, which is not a standard practice yet.

NCT ID: NCT03426865 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Role of Axumin PET Scan in Germ Cell Tumor

TESTPET
Start date: March 1, 2018
Phase:
Study type: Observational

Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

NCT ID: NCT03360994 Active, not recruiting - Testicular Cancer Clinical Trials

WATChmAN Virtual Testicular Cancer Clinic

Start date: December 15, 2017
Phase: N/A
Study type: Interventional

Princess Margaret's Multidisciplinary Testicular Cancer (TCa) Clinic sees over 25% of Ontario's testicular cancer patients, many of whom travel long distances. Fortunately, the majority of cases are confined to the testicle and are managed by "active surveillance" (AS), whereby blood work and imaging at regular intervals look to detect relapse at a curable stage. This currently requires multiple clinic visits over 5-9 years. This follow-up can be time-consuming, costly, difficult to adhere to and unsatisfying for patients. The goal of this project is to develop an efficient technological platform to perform virtual cancer follow-up. The platform has been named, "WATChmAN" which stands for Web-based virtual Testicular CANcer clinic. It will provide a secure, online interface to all virtual follow-up visits as an alternative to costly and time-consuming travel for in-person visits. The investigators anticipate improved patient satisfaction and dramatic reductions in the cost of cancer care follow-up. Moreover, the investigators anticipate improved compliance, which will lead to safer care. While TCa serves as the working platform, the investigators envision the end-product to be scalable and generalizable to other cancers (e.g. prostate cancer surveillance) across the province.

NCT ID: NCT03339635 Active, not recruiting - Testicular Cancer Clinical Trials

Short-term Testosterone Replacement in Testicular Cancer Survivors

Start date: December 21, 2018
Phase: Phase 2
Study type: Interventional

To assess the effects of testosterone replacement therapy on fat mass and other components of the metabolic syndrome. A randomized double-blind placebo controlled intervention study, followed by an open-label treatment phase. Results of this pilot study will be used to design a multicenter randomized controlled study in a large group of TC survivors

NCT ID: NCT03262207 Active, not recruiting - Seminomas Clinical Trials

Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours

GAMETH
Start date: September 2016
Phase: N/A
Study type: Observational

Recent data suggest that sperm cells carry an epigenetic message during spermatogenesis and that this message is crucial for the future development of the embryo. This epigenetic signature is notably represented by methylation of genes subjected to imprinting (GSI) and the methylation of transposable elements (TE). Data on the maintenance of the imprint and of the control of TE accompanying human gametogenesis in a context of adult germinal testicular cancers, seminomas, are extremely fragmentary for tumour tissues and inexistent for gametes. The aim of this study is to determine whether patients with seminomas in comparison with fertile men carry a higher risk of presenting epigenetic alterations affecting their gametes. This study is based on the use of an existing collection of biological samples. 90 samples will be selected and split into 3 groups: - Group 1: 30 sperm samples from patients with seminomatous testicular tumours - Group 2: 30 sperm samples from fertile patients - Group 3: 30 sperm samples from infertile patients After treatment of the samples (thawing, cell sorting and removal of cryoprotectants), they will be analysed.

NCT ID: NCT03142802 Active, not recruiting - Testicular Cancer Clinical Trials

Low-Dose CT - Stage I Testicular Cancer

Start date: September 16, 2005
Phase: N/A
Study type: Interventional

Patients with primary germ cell cancer of the testicles confined to the testis can avoid adjuvant treatment by entering a surveillance protocol. In the surveillance protocol, patients are followed for up to ten years with serial computed tomography scans to detect recurrence. Multiple CT scans expose patients to a significant amount of radiation, which may be associated with an increased risk of secondary malignancies. This study hypothesizes that low dose CT scans are as effective as standard dose CT scans in detecting disease recurrence in this setting and will significantly reduce radiation exposure in this group of patients.

NCT ID: NCT02572934 Active, not recruiting - Testicular Cancer Clinical Trials

Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study)

STANDBY
Start date: August 2015
Phase:
Study type: Observational

Depending on disease stage, testicular cancer (TC) treatment consists of an orchidectomy, alone or followed by radiotherapy (RT) or platinum-based chemotherapy (CT). TC survival rates are above 90% nowadays, which results in growing TC survivor population. Because of the long life expectancy of these survivors, prevention or early detection of late treatment effects has become increasingly relevant. Yet known late effects are nephrotoxicity, cardiovascular disease (CVD), secondary malignant neoplasms (SMN), neurotoxicity, pulmonary toxicity, Raynaud's phenomenon, hypogonadism, fatigue and psychosocial problems. Nephrotoxicity is an important late effect, but data is lacking in very long-term survivors since performed studies have a follow-up duration of 5-14 years. Decreased renal function is a known risk factor for CVD development and also an association between renal function and neurtoxicity via circulating platinum levels has been shown. It is hypothesized that treatment induced nephrotoxicity is prevalent in TC survivors and might be a mediator for development of late effects. The secondary aim is to assess prevalence of late effects in very long-term TC survivors: until now, most data have been collected through questionnaires in large epidemiological studies in TC survivors till approximately 10 years after treatment. The prevalence of late effects may increase over time: 10 years after treatment late effects may not be present yet, whilst late effects can emerge just after 20 years. Consequently, health status and possible late effects, resulting in morbidity, are underestimated in patients who are 20-30 years after treatment. By investigating health status of these very long-term survivors a more profound insight in the prevalence and aetiology of these late effects and the development over time can be assessed. Current treatment is very similar to TC treatment 20-30 years ago and therefore knowledge on late effects is relevant for currently treated patients. Furthermore, as a result of this study, we will better understand which factors and issues should be watched closely during follow-up, which TC survivors are at increased risk of developing late treatment effects and how to detect early damage before overt morbidity occurs.